Skip to main navigation
  • Contact Us
  • Global
    • International
    • Canada
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands
    • Spain
Amicus Therapeutics
  • About Amicus
    • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Programs & Pipeline
    • Our Pipeline
    • Fabry Disease
    • Pompe Disease
    • Batten Disease
    • Additional Preclinical Programs
    • Clinical Trials
    • Platform Technologies
    • Journal Articles
    • Publications & Posters
  • Product
    • Product
    • Galafold®
    • Amicus Assist™
  • Responsibility
    • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Investors & Media
    • Investor Relations
    • Senior Management Team
    • Board of Directors
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports and Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Contact Us
    • Sign Up for Email Alerts
  • Careers
    • Careers
    • Overview
    • Search

Investors

Press Releases

Press Releases

May 10, 2023
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 2, 2023
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 1, 2023
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
April 26, 2023
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
March 27, 2023
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
March 1, 2023
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
February 27, 2023
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 22, 2023
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
February 14, 2023
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
February 13, 2023
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
  • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Pipeline
    • Our Programs
    • Clinical Trials
    • Platform Technologies
    • Publications & Posters
    • Journal Articles
  • Product
    • Overview
    • Amicus Assist™
  • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports & Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Featured Coverage
  • Careers
    • Overview
    • Search
  • Social Media
    • Twitter
    • YouTube
    • LinkedIn
Copyright © 2023 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119
  • Cookies Statement
  • Terms of Use
  • Privacy Notice
  • Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional